<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115474</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-21448</org_study_id>
    <nct_id>NCT05115474</nct_id>
  </id_info>
  <brief_title>Study of Screening Brain MRIs in Stage IV Breast Cancer</brief_title>
  <official_title>Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Florida Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single arm, nonrandomized phase II prospective study, with the goal of&#xD;
      investigating the role of screening brain MRIs in neurologically asymptomatic patients with&#xD;
      metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Brain Metastasis</measure>
    <time_frame>at Baseline</time_frame>
    <description>Rate of brain metastasis by breast cancer subtype at baseline using MRI images.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Brain Metastasis</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Rate of brain metastasis by breast cancer subtype at 6 months or first systemic progression using MRI images.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Asymptomatic Leptomeningeal Disease</measure>
    <time_frame>Baseline and at up to 6 months</time_frame>
    <description>Rate of asymptomatic leptomeningeal disease by breast cancer subtype at baseline and at 6 months or first systemic progression, using MRI images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Brain Metastases</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of Brain Metastases at Diagnosis by Breast Cancer Subtype, using MRI images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Overall Survival (OS) will be measured from the initial on study date to the recorded date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Whole Brain Radiation Therapy vs Stereotactic Radiation</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of Participants Requiring Whole Brain Radiation Therapy vs Stereotactic Radiation by breast cancer type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Metastasis Specific Survival</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Brain metastasis specific survival following brain metastasis by breast cancer subtype</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Hormone Receptor-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Participants with TNBC (triple negative breast cancer)</arm_group_label>
    <description>Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer</arm_group_label>
    <description>Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Hormone Receptor (HR) +Breast Cancer</arm_group_label>
    <description>Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Participants will undergo MRI imaging with and without contrast.</description>
    <arm_group_label>Participants with Hormone Receptor (HR) +Breast Cancer</arm_group_label>
    <arm_group_label>Participants with Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer</arm_group_label>
    <arm_group_label>Participants with TNBC (triple negative breast cancer)</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be collected to evaluate changes in surrogate biomarkers related to brain&#xD;
      metastasis progression. Changes in biomarkers such as cytokines associated with T-cell&#xD;
      activation and lymphocyte subpopulations may provide evidence of brain metastasis&#xD;
      progression. Furthermore, circulating tumor DNA may identify populations of patients more&#xD;
      likely to undergo CNS progression&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stage IV breast cancer patients at Moffitt Cancer Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status&#xD;
&#xD;
          -  Radiographic evidence of stage IV extracranial disease having progressed past first&#xD;
             line therapy&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0 to 2&#xD;
&#xD;
          -  Patients must be able to understand and the willingness to sign an informed consent&#xD;
             for study procedures&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior diagnosis or treatment of brain metastases or leptomeningeal disease&#xD;
&#xD;
          -  Patients with prior history of non-breast cancer malignancies should have no evidence&#xD;
             of disease ≥ 2 years&#xD;
&#xD;
          -  Neurologic symptoms warranting standard screening brain MRI in the judgement of the&#xD;
             treating physician at time of enrollment&#xD;
&#xD;
          -  Indications warranting brain MRI for other neurologic conditions at time of study&#xD;
             entry&#xD;
&#xD;
          -  Contraindication towards MRI imaging with contrast&#xD;
&#xD;
          -  Chronic kidney disease stage IV or V or end stage renal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamran A Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle DeJesus</last_name>
    <phone>813-745-6911</phone>
    <email>Michelle.DeJesus@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle DeJesus</last_name>
      <phone>813-745-6911</phone>
      <email>Michelle.DeJesus@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Avan Armaghani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Arrington, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Costa, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Diaz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Han, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung Khong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimberley Lee, MD, MHS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loretta Loftus, MD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marilin Rosa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hatem Soliman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aixa Soyano Muller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iman Washington, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage IV Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

